News
Position of Generic Drugs in Oncology: What Are Their Main Advantages?
Generics – as is well known – are products containing the same active substance as the original medicinal product, which can enter the market after the patent protection of the original drug has expired. They are applied in various medical fields, including oncology. The main goal of producing generics is to improve the accessibility of treatment for a wide range of patients while maintaining the safety and effectiveness of the therapy.
Monocyte Distribution Width as a New Indicator of Sepsis in High-Risk Patients
Most septic patients are first encountered in the emergency department, where sepsis detection is…
New Hematological Biomarker for Early Diagnosis of Sepsis
Sepsis is one of the leading causes of mortality and healthcare expenditure worldwide. Early…
Interstitial Lung Processes and Their Fibrotic Progression
Interstitial lung processes (ILPs) include more than 200 clinical units that share diffuse…
Evaluation of Continuity of Care in Patients with mCRC – Baseline Characteristics of Participants in the PROMETCO Study
During this year's World Congress of the European Society for Medical Oncology (ESMO) on gastrointestinal...
Trifluridine/tipiracil in Real Clinical Practice – Current Data from Spain
Trifluridine/tipiracil is indicated for the treatment of patients with refractory metastatic colorectal...
Evaluation of Treatment Response in CLL
The size of lymph nodes, liver, spleen, blood cell counts, systemic symptoms... Changes in these indicators...
Idiopathic Pulmonary Fibrosis: Can This Disease Be Named More Precisely?
Much about idiopathic pulmonary fibrosis (IPF) is still unknown. Some experts would like to…
Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy – Results of the Final Analysis of Clinical Studies
Previously published results of clinical studies have shown that in patients refractory to…
Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against…
Popular this week
- “Clinical Research Bites” – 2025/39
- Probiotics in antibiotic treatment – an overview of effectiveness, risks, and recommended practices
- How Can VR Glasses Serve as a Diagnostic Tool for Dementia?
- Stem Cells Open the Door to New Treatment Possibilities for Multiple Sclerosis
- New Platform May Accelerate Diagnosis of Alzheimer’s Disease